Zom stock forecast medium-term zom stock forecast

Medium-term zom stock forecast simulations point towards a gradual climb as industry consolidation improves competitive positioning. In the event this happens, sentiment for SurgePays could turn on a dime. Prior forecasts called for the company to earn as much as 80 cents per share in 2025. Hence, a positive turn of events would likely send this $3.19 per share stock back to double-digit price levels. Add in other catalysts, like SurgePays’ move into prepaid wireless, and there may be a longshot chance of an eventual tenfold move higher. With SURG, keep in mind the high risk, but don’t discount the potential high rewards. Also, Truforma is a recurring revenue product and veterinarians would have to buy cartridges frequently based on their usage. While the forecasts provided by companies, especially penny names, should be taken with a pinch of salt, I find ZOM worth betting on for the long term. Market sentiment is mixed, as investors weigh pandemic recovery-driven growth against competitive pressures in the food delivery sector. Analysts are monitoring quarterly revenue trends closely.